Skye Bioscience, Inc. (SKYE)
Develops drugs that reduce appetite and aid weight loss by targeting metabolic receptors
$0.61-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-82.0%
The outlook
SKYE trades near its 52-week low, well below both its 50- and 200-day moving averages, suggesting a downtrend. Analysts lean bullish with an average rating of Buy, and the consensus price target sits roughly 11x above the current price. The stock remains thinly valued but faces considerable headwinds based on recent price action.
What’s behind the score
Analyst consensusBuy — 1.9 avg of 6 analysts
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +1093% vs current price
Analyst price target
~12-month · 6 analysts$7.33average target+1092.6% vs now
Now $0.61
Low $2.00High $20.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$21.6M
52-wk high
$4.99
52-wk low
$0.57
50-day avg
$0.72
200-day avg
$0.93
Trailing P/E
—